Understanding how stress affects immune response in aggressive breast cancer
Identifying the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancer
['FUNDING_R03'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10727051
This study is looking at how stress affects the immune system in people with triple negative breast cancer, to see if managing stress can help make cancer treatments work better.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10727051 on ClinicalTrials.gov |
What this research studies
This research investigates the impact of stress on the immune response in patients with triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer. It focuses on how stress-induced changes in certain molecules may hinder the effectiveness of immune checkpoint inhibitors, which are treatments designed to help the immune system fight cancer. By studying the relationship between psychosocial stress and immune response, the research aims to identify new strategies to improve treatment outcomes for TNBC patients. The approach includes examining the expression of specific chemokines that are crucial for attracting immune cells to tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer who may be experiencing significant psychosocial stress.
Not a fit: Patients with other types of breast cancer or those not experiencing stress-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for triple negative breast cancer patients, enhancing their response to existing therapies.
How similar studies have performed: Previous research has indicated that stress can negatively impact cancer treatment outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GANDHI, SHIPRA — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: GANDHI, SHIPRA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.